Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that BJ045 for Injection has been approved by China’s National Medical Products Administration (NMPA) for the commencement of clinical trials — advancing a differentiated subcutaneously administered anti‑CD20 antibody designed to resist degradation by IgG‑degrading enzymes and to enable deep B‑cell depletion in combination with the company’s own IgG‑degrading enzyme, KJ103, in moderate‑to‑severe autoimmune diseases.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval (IND) |
| Product | BJ045 for Injection (subcutaneous) |
| Drug Class | Anti‑CD20 monoclonal antibody – enzyme‑resistant design |
| Intended Setting | Potential treatment of moderate‑to‑severe autoimmune diseases, in combination with IgG‑degrading enzymes such as KJ103 |
| Approval Date | 19 Oct 2026 |
| Next Steps | Clinical trial initiation; phase design and timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: BJ045, an anti‑CD20 antibody for subcutaneous administration, independently developed by Bao Pharmaceuticals.
- Enzyme‑Resistant Innovation: Engineered to be resistant to degradation by IgG‑degrading enzymes — enabling co‑administration with agents such as KJ103, the company’s IgG‑degrading enzyme candidate, without loss of antibody integrity.
- Epitope Specificity Retained: While resistant to enzymatic cleavage, BJ045 retains specific binding to the CD20 type II epitope — the binding site associated with non‑internalizing, direct cell‑death‑promoting anti‑CD20 mechanisms.
- Enhanced Fc Effector Function: A differentiated Fc design significantly enhances affinity for Fc receptors on effector cells and increases ADCC (antibody‑dependent cellular cytotoxicity) activity.
- Deep B‑Cell Depletion: The combined engineering is intended to facilitate deep depletion of CD20‑positive B cells in both peripheral blood and tissues — going beyond the partial depletion typical of conventional anti‑CD20 therapy.
Combination Strategy – BJ045 + KJ103
- Synergistic Design: In moderate‑to‑severe autoimmune disease, pathogenic autoantibodies are a central driver; IgG‑degrading enzymes such as KJ103 rapidly cleave circulating IgG, while BJ045 eliminates the CD20‑positive B cells that replenish them.
- Overcoming the Conventional Conflict: Standard anti‑CD20 antibodies are themselves IgG molecules and would be degraded by IgG‑degrading enzymes; BJ045’s enzyme‑resistant design resolves this conflict — a first‑of‑kind complementarity within a single company’s pipeline.
- Therapeutic Rationale: The pairing is positioned to deliver rapid autoantibody reduction plus deep, sustained B‑cell depletion — potentially resetting humoral immunity in refractory autoimmune indications.
- Disclosures: Specific autoimmune indications, trial design, and combination dosing strategy were not disclosed in the announcement.
Market Impact & Outlook
- Pipeline Synergy: For Bao Pharmaceuticals, the IND advance links BJ045 directly to its KJ103 franchise, creating an internally paired combination strategy in autoimmune disease with differentiated mechanistic logic.
- Anti‑CD20 Differentiation: In a crowded anti‑CD20 landscape defined by rituximab biosimilars and next‑generation antibodies, BJ045 competes on enzyme resistance, type II epitope binding, enhanced ADCC and subcutaneous delivery — a multi‑axis differentiation profile.
- Autoimmune Opportunity: Moderate‑to‑severe autoimmune diseases with pathogenic‑antibody mechanisms (such as autoantibody‑mediated conditions refractory to standard care) represent a large and growing biologics market where rapid IgG degradation plus B‑cell depletion is an emerging therapeutic concept.
- Disclosures: Clinical development timeline, indication selection, and commercial forecasts were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, combination strategy, regulatory pathway, and commercialization expectations for BJ045 and its potential use with KJ103. Actual results may differ materially due to risks including clinical trial outcomes, NMPA review requirements, competitive dynamics in the anti‑CD20 and autoimmune biologics markets, and combination‑therapy execution. Clinical trial approval does not guarantee eventual marketing authorization.-Fineline Info & Tech
